Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.

Recent & Breaking News (NDAQ:ACOR)

CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinson’s Disease

Business Wire June 5, 2017

Acorda to Present at the Goldman Sachs Healthcare Conference

Business Wire May 31, 2017

Biotech Stocks on Investors' Radar -- Achillion Pharma, Acorda Therapeutics, Aralez Pharma, and Regulus Therapeutics

PR Newswire May 26, 2017

Acorda to Present New INBRIJA™ (Levodopa Inhalation Powder) Phase 3 Data at Upcoming MDS Congress

Business Wire May 18, 2017

Acorda to Present at the Deutsche Bank 42nd Annual Healthcare Conference

Business Wire May 2, 2017

Acorda Expands Alexa Skill Offering for Parkinson’s Awareness Month

Business Wire April 28, 2017

Acorda Provides Financial and Pipeline Update for First Quarter 2017

Business Wire April 27, 2017

Acorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017

Business Wire April 13, 2017

ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm

PR Newswire April 7, 2017

Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs

Business Wire April 5, 2017

Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher  March 31, 2017

U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling

Business Wire March 31, 2017

Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient  March 31, 2017

Acorda Announces Long-Term Safety Data for CVT-301

Business Wire March 29, 2017

The Growth of the Regenerative Medicines Market

PR Newswire March 28, 2017

Research Reports Initiation on Biotech Stocks -- Radius Health, Acorda, PhaseRx, and Athersys

PR Newswire March 22, 2017

Acorda Launches Alexa Skill in Conjunction with MS Awareness Month

Business Wire March 13, 2017

Patent Trials and Appeal Board (PTAB) Upholds Four AMPYRA® Patents

Business Wire March 9, 2017

Watch These 7 Huge Put Purchases In Monday Trade  March 6, 2017

Acorda to Present at the Cowen and Company 37th Annual Healthcare Conference

Business Wire February 27, 2017